Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

NCT02039336 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Dacomitinib
DRUG: PD-0325901
DRUG: Docetaxel

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]